Immix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?

Key Points

• Immix's shares rose about 12% intraday to $9.80 on Thursday with 465,358 shares traded (≈46% below average), and its 50‑day SMA ($8.34) sits well above the 200‑day SMA ($5.64), signaling recent upward momentum.
• Analysts are mixed but tilted positive: the consensus is a "Moderate Buy" with an average price target of $18.25 (four Buys, one Hold, one Sell), and several firms recently raised targets into the $15–$23 range.
• Immix is a clinical‑stage immuno‑oncology company (lead asset IMX‑110); it reported Q1 EPS of ($0.28) (miss) and is forecast to post about ($0.87) EPS for the year, with a market cap near $509M.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report)'s share price traded up 12% during mid-day trading on Thursday . The stock traded as high as $9.79 and last traded at $9.8020. 465,358 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 865,296 shares. The stock had previously closed at $8.75.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Mizuho increased their price objective on shares of Immix Biopharma from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Monday, March 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Citizens Jmp reiterated a "market outperform" rating and set a $23.00 target price on shares of Immix Biopharma in a report on Friday, March 27th. Wall Street Zen downgraded Immix Biopharma from a "hold" rating to a "sell" rating in a report on Sunday, March 15th. Finally, HC Wainwright raised their target price on Immix Biopharma from $12.00 to $15.00 and gave the company a "buy" rating in a report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $18.25.

Immix Biopharma Stock Performance

The stock has a market cap of $508.99 million, a price-to-earnings ratio of -10.80 and a beta of 0.20. The business's fifty day simple moving average is $8.34 and its 200 day simple moving average is $5.64.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.12). As a group, analysts forecast that Immix Biopharma, Inc. will post -0.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Immix Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Kera Capital Partners Inc. purchased a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $68,000. Virtu Financial LLC purchased a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $386,000. KVP Capital Advisors LP purchased a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $1,205,000. XTX Topco Ltd boosted its stake in shares of Immix Biopharma by 32.0% during the 4th quarter. XTX Topco Ltd now owns 46,394 shares of the company's stock valued at $243,000 after buying an additional 11,241 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $116,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.